Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry

✍ Scribed by F. Tubach; D. Salmon; P. Ravaud; Y. Allanore; P. Goupille; M. Bréban; B. Pallot-Prades; S. Pouplin; A. Sacchi; R. M. Chichemanian; S. Bretagne; D. Emilie; M. Lemann; O. Lorthololary; X. Mariette

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 147 KB
• Volume: 60
• Category: Article
• ISSN: 0004-3591
• DOI: 10.1002/art.24632